 Avalon GloboCare Corp NASDAQ:AVCO said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor-Natural Killer CAR-NK cell therapies. Natural killer NK cells constitute an important component of the immune system. 